http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010109449-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate | 2008-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010109449-A |
| titleOfInvention | PHARMACEUTICAL COMPOSITION, INCLUDING SGLT2 INHIBITOR IN COMBINATION WITH DPP-IV INHIBITOR |
| abstract | 1. A pharmaceutical composition comprising an SGLT2 inhibitor selected from the group consisting of! (1) dapagliflozin,! (2) remogliflozin or etogonate remogliflosin,! (3) sergliflozin or sergliflozin etabonate,! (4) 1-chloro-4- (β-D-glucopyranos-1-yl) -2- (4-ethylbenzyl) benzene,! (5) (1S) -1,5-anhydro-1- [5- (azulen-2-ylmethyl) -2-hydroxyphenyl] -D-sorbitol,! (6) (1S) -1,5-anhydro-1- [3- (1-benzothien-2-ylmethyl) -4-fluorophenyl] -D-sorbitol,! (7) a thiophene derivative of the formula (7-1)! ! where R is a methoxy group or a trifluoromethoxy group,! (8) 1- (β-D-glucopyranosyl) -4-methyl-3- [5- (4-fluorophenyl) -2-thienylmethyl] benzene,! (9) a derivative of the spiroketal of the formula (9-1)! ! where R is a methoxy group, a trifluoromethoxy group, an ethoxy group, ethyl, isopropyl or tert-butyl,! or their pharmaceutically acceptable salt, hydrate or solvate,! in combination with a DPP-IV inhibitor of formula (I)! ! or formulas (II)! ! or formula (III)! ! or formula (IV)! ! where R1 is ([1,5] naphthyridin-2-yl) methyl, (quinazolin-2-yl) methyl, (quinoxalin-6-yl) methyl, (4-methylquinalosin-2-yl) methyl, 2-cyanobenzyl, (3-cyanoquinolin-2-yl) methyl, (3-cyanopyridin-2-yl) methyl, (4-methylpyrimidin-2-yl) methyl or (4,6-dimethylpyrimidin-2-yl) methyl, and R2 is 3 - (R) -aminopiperidin-1-yl, (2-amino-2-methylpropyl) methylamino or (2- (S) -aminopropyl) methylamino group or a pharmaceutically acceptable salt thereof. ! 2. The pharmaceutical composition according to claim 1, where the DPP-IV inhibitor is selected from the group comprising! 1 - [(4-methylquinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (R) -aminopiperidin-1-yl) xanthine,! 1 - [([1,5] naphthyridin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8 - ((R) -3-aminopiperidin-1-yl) xanthine ! 1 - [(quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8 - ((R) -3-aminopiperidin-1-yl) xanthine,! 2 - ((R) -3-aminopiperidin-1-yl) -3- (but-2-ynyl) -5 (4-methylquin |
| priorityDate | 2007-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.